NCT06646770Not yet recruiting
SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)
Segmentectomy Versus Lobectomy in Clinical T1c Non-Small Cell Lung Cancer: A Non-Inferiority Trial
Source: ClinicalTrials.gov · Last updated 17 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to investigate the role of segmentectomy in clinical T1c (2-3 cm) non-small cell lung cancer (NSCLC). The main questions we aim to answer are: 1. Is segmentectomy non-inferior to lobectomy in cT1c NSCLC in terms of overall and recurrence free survival? 2. What are the mortality and morbidity rates of segmentectomy compared to lobectomy? Researchers will compare segmentectomy and lobectomy in terms of overall and recurrence free survival. Participants will: * Undergo either pulmonary lobectomy or segmentectomy with mediastinal nodal dissection * Be followed up with a chest CT in every 3 months in first year, every 6 months in second year and every year for following 3 years
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 16 Oct 2024
- Start date
- Jan 2025
- Primary completion date
- Jan 2030
- Lead sponsor
- Istanbul University - Cerrahpasa
- Diseases
- Lung cancer
- NCT number
- NCT06646770
What you commit to
- Study type: Interventional
- Planned participants: 400
- From Jan 2025 to the primary completion date, Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major comorbidity that precludes surgery
Other illness
- Pathologically confirmed N2 or N3 disease
- Prior malignancy in five years
Other
- Pure GGO lesions
- Pathologic diagnosis other than NSCLC
- Technically not suitable for simple or complex segmentectomy, or lobectomy
- Evidence of distant metastasis
- Intraoperative mediastinal nodal dissection of less than 3 lymph node stations
Who the study is looking for
- Clinical T1c NSCLC
- Parenchymal nodule \>2 cm in diameter
- Parenchymal nodule ≤3 cm in diameter
- Consolidation / Tumor Rate (CTR) ≥ 0.50
- Definitive pathological diagnosis of NSCLC preoperative or intraoperatively
- No evidence of distant metastasis
- No evidence of N2 disease
- Adequate pulmonary functions for lobectomy or segmentectomy
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.